Plerixafor is a CXCR4 antagonist used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.

Brand Names
Generic Name
DrugBank Accession Number

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.5,9 It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.6,9

As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α). Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels.5 Compared to placebo with G-CSF, the plerixafor and G-CSF mobilization regimen has a higher probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures.3

Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.5,9

Small Molecule
Approved, Investigational
Average: 502.782
Monoisotopic: 502.447143768
Chemical Formula
  • 1,1'-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane
  • 1,4,8,11-tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-
  • Plerixafor



Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.9

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Plerixafor is a bicyclam derivative that antagonizes C-X-C chemokine receptor type 4 (CXCR4) by binding to three acidic residues in the ligand-binding pocket: Asp171, Asp262, and Glu288.7,10 Blood levels of CD34+ cells peaked between 6 and 9 hours after the administration of 0.24 mg/kg plerixafor in healthy subjects. In combination with a granulocyte-colony stimulating factor (G-CSF), circulating CD34+ cells in the peripheral blood peaked between 10 and 14 hours. The use of plerixafor is not associated with QT/QTc prolongation at single doses up to 0.40 mg/kg.9

Serious hypersensitivity reactions, such as anaphylactic-type reactions, have occurred in patients receiving plerixafor. The use of plerixafor may also cause tumor cell mobilization in leukemia patients, splenic enlargement and rupture, embryo-fetal toxicity, and hematologic effects, such as leukocytosis and thrombocytopenia. When used in combination with G-CSF for hematopoietic stem cell mobilization‚ plerixafor may lead to the release of tumor cells from the marrow and their subsequent collection in the leukapheresis product.9

Mechanism of action

Plerixafor inhibits the C-X-C chemokine receptor type 4 (CXCR4) on CD34+ cells and reversibly blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α). SDF-1α and CXCR4 play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. In the marrow, stem cell CXCR4 can help anchor HSCs to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. By blocking the interaction between SDF-1α and CXCR4 with plerixafor, the mobilization of progenitor cells is triggered. Adding granulocyte-colony stimulating factor (G-CSF) to enhance CD34+ cell mobilization increases the yield of stem cells, an important determinant of graft adequacy.1,2,9

AC-X-C chemokine receptor type 4

Plerixafor follows a two-compartment pharmacokinetic profile with first-order absorption and exhibits linear kinetics between 0.04 mg/kg and 0.24 mg/kg. The pharmacokinetic profile of plerixafor in healthy subjects was similar to the one observed in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) who received plerixafor in combination with granulocyte-colony stimulating factor (G-CSF). In addition, the clearance of plerixafor has a significant relationship with creatinine clearance (CLCR). The population pharmacokinetic analysis showed that, with increasing body weight, a mg/kg-based dosage leads to a higher plerixafor exposure (AUC0-24h). However, NHL patients (<70 kg) given a fixed dose of 20 mg of plerixafor had an AUC0-10h 1.43-fold higher than the one detected in patients given 0.24 mg/kg of plerixafor. Therefore, a body weight of 83 kg was selected as an appropriate cut-off point to transition patients from fixed to weight-based dosing.9

Peak concentrations are reached in approximately 30-60 minutes (tmax) following subcutaneous injection.9,10 In patients given 0.24 mg/kg of plerixafor subcutaneously after receiving 4-days of G-CSF pre-treatment, the Cmax and AUC0-24 were 887 ng/ml and 4337 ng·hr/ml, respectively.10

Volume of distribution

Plerixafor has an apparent volume of distribution of 0.3 L/kg.9

Protein binding

The human plasma protein binding of plerixafor is up to 58%.9


Plerixafor is not metabolized by the liver and is not a metabolism-dependent inhibitor of major cytochrome P450 enzymes, including 1A2, 2C9, 2C19, 2D6 and 3A4. In addition, it does not induce cytochrome P450 1A2, 2B6, or 3A4 enzymes.9 Plerixafor is metabolically stable, and in vivo studies in rats and dogs showed that the non-parent radiolabelled components in plasma and urine were Cu2+ complexes with plerixafor. This is consistent with the presence of two cyclam rings in plerixafor, which may act as potential chelating sites.13

Route of elimination

Plerixafor is mainly eliminated through urine. In healthy volunteers with normal renal function given 0.24 mg/kg of plerixafor, approximately 70% of the parent drug is excreted in urine in the first 24 hours. An in vitro study with MDCKII and MDCKII-MDR1 cell models found that plerixafor is not a substrate or inhibitor of P-glycoprotein.9


Plerixafor has a distribution half-life of 0.3 hours and a terminal population half-life of 5.3 hours in patients with normal renal function. In studies with healthy subjects and patients, the terminal half-life in plasma ranges between 3 and 5 hours.9 In patients with non-Hodgkin lymphoma, the terminal half-life of plerixafor is 4.4 hours, and in patients with multiple myeloma, the terminal half-life is 5.6 hours.4


Plerixafor has a total plasma clearance of 4.38 L/h, and a renal clearance of 3.15 L/h.4,8

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

There is limited data about the effects of plerixafor at doses higher than the recommended (0.24 mg/kg subcutaneously). However, the frequency of gastrointestinal disorders, vasovagal reactions, orthostatic hypotension, and/or syncope may be higher.9 The carcinogenicity of plerixafor has not been evaluated, and the effect of plerixafor on human fertility is unknown. According to the results from an in vitro bacterial mutation assay, an in vitro chromosomal aberration test, and an in vivo bone marrow micronucleus test in rats after subcutaneous doses up to 25 mg/kg, plerixafor is not genotoxic.9 In mice and rats, the LD50 of plerixafor by intravenous injection is 5 mg/kg. The LD50 of plerixafor by subcutaneous injection is 16 mg/kg in mice and >50 mg/kg in rats/.11

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirAbacavir may decrease the excretion rate of Plerixafor which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Plerixafor which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Plerixafor which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
No interactions found.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Plerixafor octahydrochlorideOD49913540155148-31-5UEUPDYPUTTUXLJ-UHFFFAOYSA-N
International/Other Brands
Mozobil (Genzyme Corporation)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MozobilSolution20 mg / mLSubcutaneousSanofi Aventis2012-03-26Not applicableCanada flag
MozobilInjection, solution20 mg/mlSubcutaneousSanofi B.V.2020-12-23Not applicableEU flag
MozobilInjection, solution24 mg/1.2mLSubcutaneoussanofi-aventis U.S. LLC2013-09-01Not applicableUS flag
MozobilSolution24 mg/1.2mLSubcutaneousGenzyme Corporation2008-12-152018-03-23US flag
Plerixafor AccordInjection, solution20 mg/mlSubcutaneousAccord Healthcare S.L.U.2023-02-08Not applicableEU flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PlerixaforSolution24 mg/1.2mLSubcutaneousMeitheal Pharmaceuticals Inc.2023-07-24Not applicableUS flag
PlerixaforInjection, solution24 mg/1.2mLSubcutaneousGland Pharma Limited2024-05-03Not applicableUS flag
PlerixaforInjection24 mg/1.2mLSubcutaneousZydus Lifesciences Limited2023-07-28Not applicableUS flag
PlerixaforInjection, solution24 mg/1.2mLSubcutaneousNovadoz Pharmaceuticals Llc2023-07-25Not applicableUS flag
PlerixaforSolution24 mg/1.2mLSubcutaneousDr. Reddy's Laboratories Inc2023-11-06Not applicableUS flag


ATC Codes
L03AX16 — Plerixafor
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
Organic compounds
Super Class
Benzene and substituted derivatives
Sub Class
Direct Parent
Alternative Parents
Benzylamines / Aralkylamines / Trialkylamines / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Amine / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzylamine / Hydrocarbon derivative / Organic nitrogen compound / Organoheterocyclic compound / Organonitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key


Synthesis Reference

Xu, D., et al. (1997). Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (U.S. Patent No. 5,612,478 A). U.S. Patent and Trademark Office.

General References
  1. Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . [Article]
  2. Fricker SP: A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60. doi: 10.1517/13543784.17.11.1749 . [Article]
  3. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. doi: 10.1182/blood-2008-08-174946. Epub 2009 Apr 10. [Article]
  4. Stewart DA, Smith C, MacFarland R, Calandra G: Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018. [Article]
  5. Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 2010;78(3-4):282-8. doi: 10.1159/000315736. Epub 2010 Jun 8. [Article]
  6. Choi HY, Yong CS, Yoo BK: Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother. 2010 Jan;44(1):117-26. doi: 10.1345/aph.1M380. Epub 2009 Dec 15. [Article]
  7. Keating GM: Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. [Article]
  8. MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G: A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant. 2010 Jan;16(1):95-101. doi: 10.1016/j.bbmt.2009.09.003. Epub 2009 Sep 10. [Article]
  9. FDA Approved Drug Products: MOZOBIL (plerixafor) injection for subcutaneous use (August 2020) [Link]
  10. EMA Summary of Product Characteristics: Mozobil (plerixafor) injection solution for subcutaneous use (April 2014) [Link]
  11. FDA Pharmacology Review: Mozobil (plerixafor) injection (December 2008) [Link]
  12. Toronto Research Chemicals: Plerixafor SDS [Link]
  13. CHMP Assessment Report: Mozobil (plerixafor) [Link]
Human Metabolome Database
PubChem Compound
PubChem Substance
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
RxList Drug Page Drug Page
PDB Entries

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedTreatmentAutologous hematopoietic stem cell transplant1somestatusstop reasonjust information to hide
4CompletedTreatmentDiabetes1somestatusstop reasonjust information to hide
4CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1somestatusstop reasonjust information to hide
4RecruitingTreatmentLymphoma1somestatusstop reasonjust information to hide
4Unknown StatusTreatmentAutologous Stem Cell Transplantation1somestatusstop reasonjust information to hide


Not Available
Not Available
Dosage Forms
Injection, solutionParenteral; Subcutaneous20 MG/ML
Injection, solutionSubcutaneous24 mg/1.2mL
SolutionSubcutaneous20 mg / mL
SolutionSubcutaneous24 mg/1.2mL
SolutionSubcutaneous24.000 mg
SolutionSubcutaneous20 mg/ml
Injection, solutionSubcutaneous20 mg/ml
SolutionSubcutaneous24 mg
InjectionSubcutaneous24 mg/1.2mL
Injection, solution20 MG/ML
Injection, solutionParenteral20 mg/ml
Injection, solution20 mg/1ml
SolutionSubcutaneous20 mg/1ml
Not Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6987102No2006-01-172023-07-22US flag
US7897590No2011-03-012023-03-22US flag
USRE42152No2011-02-152018-12-10US flag


Experimental Properties
melting point (°C)131.5 °CFDA label
water solubilitySlightly solubleSDS
pKa8.5-11.5 and <2.4CHMP Assessment Report
Predicted Properties
Water Solubility0.0472 mg/mLALOGPS
pKa (Strongest Basic)10.23Chemaxon
Physiological Charge4Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area78.66 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity155.01 m3·mol-1Chemaxon
Polarizability60.65 Å3Chemaxon
Number of Rings3Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Human Intestinal Absorption+0.932
Blood Brain Barrier+0.6867
Caco-2 permeable-0.5403
P-glycoprotein substrateSubstrate0.8076
P-glycoprotein inhibitor INon-inhibitor0.8119
P-glycoprotein inhibitor IINon-inhibitor0.7683
Renal organic cation transporterInhibitor0.5069
CYP450 2C9 substrateNon-substrate0.8905
CYP450 2D6 substrateSubstrate0.5274
CYP450 3A4 substrateNon-substrate0.7818
CYP450 1A2 substrateNon-inhibitor0.8787
CYP450 2C9 inhibitorNon-inhibitor0.9272
CYP450 2D6 inhibitorNon-inhibitor0.7149
CYP450 2C19 inhibitorNon-inhibitor0.9114
CYP450 3A4 inhibitorNon-inhibitor0.8817
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.926
Ames testNon AMES toxic0.7906
BiodegradationNot ready biodegradable0.9824
Rat acute toxicity2.1178 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.6334
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0udi-1697050000-f5d2d801403d4ca1fac2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0000090000-f6127c0396058e17120f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0000090000-cfb57137af8c69fff8eb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0000090000-0c686db0669edc9df7bd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-11os-0980010000-20b211b430b392a9ffaa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0300090000-ddc0d9ecb8fc4f3b0abd
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0900200000-7c6ca6e9ee557f9dc70c
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Pharmacological action
General Function
Virus receptor activity
Specific Function
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiq...
Gene Name
Uniprot ID
Uniprot Name
C-X-C chemokine receptor type 4
Molecular Weight
39745.055 Da
  1. Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . [Article]
  2. Jujo K, Ii M, Sekiguchi H, Klyachko E, Misener S, Tanaka T, Tongers J, Roncalli J, Renault MA, Thorne T, Ito A, Clarke T, Kamide C, Tsurumi Y, Hagiwara N, Qin G, Asahi M, Losordo DW: CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation. 2013 Jan 1;127(1):63-73. doi: 10.1161/CIRCULATIONAHA.112.099242. Epub 2012 Nov 30. [Article]
  3. Pan C, Liu P, Ma D, Zhang S, Ni M, Fang Q, Wang J: Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia. Biomed Pharmacother. 2020 Oct;130:110610. doi: 10.1016/j.biopha.2020.110610. Epub 2020 Aug 12. [Article]
  4. FDA Approved Drug Products: MOZOBIL (plerixafor) injection for subcutaneous use (August 2020) [Link]

Drug created at September 14, 2010 16:21 / Updated at April 23, 2024 11:38